Crabel Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Crabel Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-423,490	Closed	-$7.44M	–	158
2021 Q3	$7.44M	Buy	+423,490	New	+$4.95M	2.29%	14

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Crabel Capital Management's TRIL Position: Q4 2021 in Review

Crabel Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 423,490 shares — an estimated $7.44M sold.

Crabel Capital Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $7.44M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Crabel Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Crabel Capital Management sold 423,490 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $7.44M.
Crabel Capital Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Crabel Capital Management's Trillium Therapeutics Inc. position peaked at $7.44M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Crabel Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.